News & Events

Upcoming Events

Tue, 12/6/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Thu, 12/8/2022 - 8:00 PM ET
For caregivers, family & friends - You don’t need to take on… more
Tue, 12/13/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more
Thu, 12/15/2022 - 6:30 PM ET
For patients/survivors - General meetup for those impacted by lung… more
Tue, 12/20/2022 - 12:00 PM ET
For patients/survivors - Join us every Tuesday for this general… more

A Wealth of Clinical Trials Pushes the Treatment Landscape Forward Across Lung Cancer

A Wealth of Clinical Trials Pushes the Treatment Landscape Forward Across Lung Cancer

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Ensartinib Approved in China for ALK+ NSCLC as 1st Line Treatment

Ensartinib Approved in China for ALK+ NSCLC as 1st Line Treatment

Pfizer: Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

Pfizer: Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer

Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC

Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing

Study Estimates Impact of Targeted Treatments in NSCLC

Study Estimates Impact of Targeted Treatments in NSCLC

LUNGevity Launches New ALK Patient Gateway'

LUNGevity Launches New ALK Patient Gateway'

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort